Pancreatic β cells secrete insulin in response to glucose levels and thus are involved in controlling blood glucose levels. A line of pancreatic β cells "MIN6" has been used in studies related to the function of β cells and diabetes therapy. Regulating gene expression in MIN6 cells could accelerate these studies, but an efficient method for the transfection of nucleic acids targeted to MIN6 cells is required. We report here on a liposome-based carrier targeted to pancreatic β cells (Multifunctional envelope-type nano device for pancreatic β cells, β-MEND). We identified a lipid composition for use in preparing the β-MEND, which permits the particles to be efficiently internalized into MIN6, as evidenced by flow cytometry analyses. Intracellular observation by confocal laser scanning microscopy showed that the β-MEND efficiently delivered the oligo nucleic acids to the cytosol of MIN6 cells. Moreover, using a β-MEND encapsulating a 2'-O-Methyl RNA complementary to a microRNA that suppresses insulin secretion, the knockdown of the targeted microRNA and an up-regulation of insulin secretion were observed in MIN6. Thus, the β-MEND holds promise as an efficient system for delivering nucleic acids targeted to MIN6 and can contribute to research and therapy aimed at diabetes.
Introduction
Diabetes mellitus is a multi-factorial disorder characterized by high blood glucose levels, and appears to be caused, in part, by genetic and environmental factors [1, 2] . Mutations of the gene related to pancreatic β cell function have been associated with some types of diabetes mellitus [3, 4] . For example, maturity-onset diabetes of the young (MODY) are caused by mutations in any one of at least six different genes that encode the glycolytic enzyme glucokinase and five transcription factors [5] . These genes are associated with important pancreatic β cell functions, including the production and secretion of insulin which regulates blood glucose levels. Therefore, gene therapy targeted to pancreatic β cells and related studies could be useful for the treatment of many patients suffering from diabetes mellitus.
A line of pancreatic β cells "MIN6" has been established from mouse insulinomas, and has morphological characteristics that are similar to those of pancreatic β cells. In addition, MIN6 cells exhibit glucose-inducible insulin secretion comparable to that of cultured normal mouse islet cells [6] . Thus, the MIN6 cell line is useful in studies of the molecular mechanisms of pancreatic β cells, and has been used in research directed to the study of the pancreatic β cells function and diabetes therapy [7] [8] [9] . The regulation of gene expression in MIN6 cells could accelerate these studies, but an efficient method for the transfection of nucleic acids targeted to MIN6 cells is required. To date, while the transfection of nucleic acids into MIN6 cells using a viral vector [9] and electroporation [8] has been achieved, the transfection efficiency does not appear to be sufficient.
Considering such a situation, a nanocarrier system capable of delivering nucleic acids targeted to MIN6 cells is essential for future research on the function of β cells and diabetes therapy.
In previous studies, we reported on the development of a multifunctional envelope-type nano device (MEND), which consists of a condensed plasmid DNA (pDNA) core and lipid envelopes [10, 11] , which showed transfection activities as high as that for a viral vector in dividing cells [12] . To date, we have been successful in efficiently packaging nucleic acids, including oligo DNA [13, 14] and siRNA [15, 16] , and showed that the MEND system achieved efficient gene silencing and RNA knockdown [14] [15] [16] [17] [18] [19] . These results prompted us to consider the possibility that a MEND system could be used to achieve the efficient cytosolic delivery of nucleic acids targeted to impregnable MIN6 cells.
In this study, we report on our attempts to develop β-MEND, which is a MEND that permits the efficient delivery of nucleic acids to pancreatic β cells. We conclude that the β-MEND reported on here, constitutes a breakthrough in research on the function of 5 β cells and diabetes therapy. We first identified a lipid composition for the β-MEND that permits it to be efficiently internalized into MIN6 cells. This was achieved by varying the lipid composition of a panel of liposomes (LPs) labelled with fluorescent lipids and cellular uptake analysis by flow cytometry. We next constructed the β-MEND in which nucleic acids were encapsulated, and the fluorescent labeled nucleic acids that were internalized in MIN6 by the β-MEND were measured by flow cytometry. We also observed the intracellular trafficking of the nucleic acids using confocal laser scanning microscopy (CLSM). Moreover, when a β-MEND encapsulating a 2'-O-Methyl (2'-OMe) RNA which targets a microRNA (miRNA) that suppresses insulin secretion was used, the knockdown of the targeted miRNA and the up-regulation of insulin secretion were observed and evaluated in MIN6 cells.
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Materials and methods
Materials
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilawroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), egg yolk phosphatidyl choline (EPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-stearoyl-2-oleoyl-snglycero-3-phosphocholine (SOPC) were obtained from Nippon Oil and Fats Co. (Tokyo, Japan). Cardiolipin (CL), cholesteryl hemisuccinate (CHEMS), phosphatidic acid (PA) and phosphatidyl grycerol (PG) were purchased from Sigma (St. Louis, MO, USA).
2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE) and sphingomyelin (SM) were purchased from Avanti Polar lipids (Alabaster, AL, USA). Stearyl octaarginine (STR-R8) [20] was obtained from KURABO Industries Ltd (Osaka, Japan). The oligo DNA (5'-CTTCTCGTCCCCATGGATGACCCC-3') and the oligo DNA labeled with fluorescent that Cy5 is conjugated to 5 terminal of the oligo DNA were obtained from Hokkaido System Science Co., Ltd (Sapporo, Japan (AAGGCAAGCUGACCCUGAAGU) were obtained from Greiner Japan (Tokyo, Japan).
Protamine was purchased from CALBIO CHEM (Darmstadt, Germany). HeLa human cervix carcinoma cells were obtained from the RIKEN Cell Bank (Tsukuba, Japan).
MIN6 cells, a mouse pancreatic beta cell line [6] , were generously provided by Dr. J.
Miyazaki (Osaka University, Japan). Dulbecco's modified Eagle medium (DMEM), fetal bovine serum (FBS), Lipofectamine Plus (LFN Plus) and tetramethylrhodamine (TMRM)
were purchased from Life Technologies Corporation (Carlsbad, CA, USA). All other chemicals used were commercially available reagent-grade products.
Cell culture and transfection studies
HeLa cells were cultured in DMEM supplemented with 10% FBS and penicillin (100 U/mL), streptomycin (100 μg/mL) under an atmosphere of 5% CO2 at 37ºC. MIN6 cells were cultured in DMEM containing 25 mM glucose and supplemented with 10%
FBS and penicillin (100 U/mL), streptomycin (50 μg /mL) under an atmosphere of 5% 
Preparation of NBD-labeled LPs
LPs were prepared by the lipid hydration method. A lipid film containing 0.5 mol% 7-nitrobenz-2-oxa-1, 3-diazole labelled DOPE (NBD-DOPE) (Avanti Polar lipids) was prepared on the bottom of a glass tube by evaporation of an ethanol solution containing 150 nmol lipids, as shown in Table 1 . Next, 250 μL of 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) was applied to the lipid film, followed by incubation for 15 min at room temperature. The lipid film was then sonicated for 30 sec in a bath-type sonicator (85 W, Aiwa Co., Tokyo, Japan). R8-modified LP (R8-LP) was prepared by mixing the LP (DOPE/PA = 9:2, molar ratio)
suspensions and an STR-R8 solution (10 mol% of lipid). 
Preparation of MEND encapsulating
Characterization of prepared carriers
Particle diameters were measured using a dynamic light scattering (DLS) method (Zetasizer Nano ZS; Malvern Instruments, Worcestershire, UK). Samples were prepared in 10 mM HEPES buffer at 25°C and the values are shown in the form of volume distribution. The ξ-potentials of samples were also determined in 10 mM HEPES buffer at 25°C using a Zetasizer Nano ZS. The encapsulation efficiency of nucleic acids (oligo DNA or 2'-OMe RNA) was determined using a fluorescent nucleic acid stain for quantitating nucleic acids, RiboGreen dye (Life Technologies Corporation) [21] , as previously reported [17] .
Quantification of the cellular uptake using flow cytometry
Cells were washed with serum-free DMEM before incubation with the carriers.
The carriers with lipid envelopes labeled with 1 mol% NBD-DOPE were added to the cells (final lipid concentration, 27.5 μM) for the experiment shown in Figure 1A and 2.
While the carriers with 5 mol% Cy5 labeled oligo DNA were used in Figure 3A Relative cellular uptake value (%) = UP/UA×100
where UP and UA represent the cellular uptake when cells were treated with carriers in the presence and absence of inhibitors, respectively.
Visualization of intracellular oligo DNAs by CLSM
The carriers in which the lipid envelopes were labeled with 1 mol% NBD-DOPE were added to the cells (final lipid concentration, 14.2 μM) for the experiment shown in Figure   1B . While the carriers with 5 mol% Cy5 labeled oligo DNA were used in Figure 3B BP 570-620 (red color) for TMRM and Ch4: BP 660-710 (green pseudo color) for Cy5.
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Evaluation for cytotoxicity
Cells were washed with serum-free DMEM before being incubated with the carriers. The carriers encapsulating oligo DNA were added to the cells (final concentration of oligo DNA, 25 -400 nM), and the cells incubated in serum-free DMEM under an atmosphere of 5% CO2 at 37ºC. After a 3-hr incubation, the medium was replaced with medium containing serum, and the cells further were incubated for 21 hr.
The cells were then washed, and the cellular protein content was determined using a BCA protein assay kit (PIERCE; Rockford, IL, USA) and an EnSpireTM 2300 Multilabel
Reader (PerkinElmer, Inc.; Waltham, MA, USA). Cell viability was calculated as follows;
Cell viability (%) = CS/CN×100
where CS and CN represent the cellular protein concentration when cells were treated with carriers encapsulating oligo DNA and non-treated cells, respectively.
RNA extraction and RT-PCR after transfection of 2'-OMe RNA into MIN6 cells
The carriers encapsulating 2'-OMe RNA (anti-miR-375) were added to the cells (final concentration of 2'-OMe RNA, 0.1 -50 nM), and the cells incubated in serum-free DMEM under an atmosphere of 5% CO2 at 37ºC. After a 3-hr incubation, the medium was replaced with medium containing serum, and the cells were incubated for a further 21 hr.
After incubation, the cells were washed three times with PBS (-), total RNA was then extracted using TRIzol reagent ( where ∆∆CT= ∆CT miR-375 (n) − ∆CT calibration (n).
Each reaction was done, at least in duplicate.
Insulin secretion studies
The carriers encapsulating 2'-OMe RNA (anti-miR-375 or control RNA) were added to the cells (final concentration of 2'-OMe RNA, 10 -100 nM), and the cells were then incubated in serum-free DMEM under an atmosphere of 5% CO2 at 37ºC. After a 3-hr incubation, the medium was replaced with medium containing serum, and the cells were For comparison between two groups, the two tail unpaired student's t-test was used. For multiple comparisons, one way ANOVA was used. P < 0.05 was considered to be statistically significant.
3. Results
Screening for a lipid composition with high affinity to MIN6 cells
We recently developed a MEND, consisting of a condensed pDNA core and lipid envelopes [10, 11] , the surface of which was modified with high-density R8, an artificially designed cell penetrating peptide [20, 22] , to produce the R8-MNED. A previous report showed that high-density R8-modified carriers were internalized primarily via macropinocytosis rather than clathrin-mediated endocytosis, as is the case of cationic LPs [23, 24] . Moreover, the R8-MEND showed transfection activities in dividing cells that were as high as that for adenovirus [12] . Based on these results, we predicted that the R8-MEND would be efficiently taken up by cells, even MIN6 cells.
To validate this issue, we evaluated the cellular uptake of R8-LP using MIN6 cells and HeLa cells, which was efficiently internalized by R8-modified carriers [12] . The diameter and ζ-potential of R8-LP (10 mol% R8 of lipids) used in this experiment were ~ 130 nm and ~ +50 mV (Table S1 ). Flow cytometry analyses indicated a low cellular uptake of R8-LPs in the case of MIN6 cells (Fig. 1A (a) ). The fluorescence intensities of R8-LPs labeled with NBD-lipids taken up by cells (pink line) were comparable with that of non-treated cells (black line), although the value for the R8-LPs (pink line) was slightly increased compared to R8-ummodified LPs (green line). On the other hand, in the case of HeLa cells (Fig. 1A (b) ), cellular uptake for the R8-LPs was much higher than that of the R8-ummodified LPs and non-treated cells. The cellular uptake values (MFI) of R8-LPs in the case of MIN6 cells and HeLa cells were ~ 7 and ~ 95, respectively (Figs. S1,   S2 ). Intracellular observation of the R8-LPs also showed that no R8-LPs were observed in MIN6 cells (Fig. 1B (a) ), while, green signals corresponding to R8-LPs labeled with NBD-lipids were observed in HeLa cells (Fig. 1B (b) ).
We screened for an LP that is efficiently internalized into MIN6 cells by varying the lipid composition of the LPs. Table 1 (Fig. 2A) . As a result, it was observed that the cellular uptake of positively charged LPs containing CL, Chol and SM were higher than that for negatively charged LPs containing PG, CHEMS and PA. In the case of A-type LPs, an SM containing LP showed the highest cellular uptake. We then evaluated the cellular uptake of B-type LPs (Lipid X/EPC/SM = 3:4:3, molar ratio), which were SM-containing LPs composed of different types of cationic lipids ( Table 1 ). The results showed that the value for the cellular uptake of a DC-Chol containing LP was the highest among the B-type LPs (Fig. 2B) , suggesting that DC-Chol is an optimal cationic lipid for the efficient internalization of LP by MIN6 cells. Finally, we investigated the cellular uptake of Ctype LPs (DC-Chol/Lipid X/SM = 3:4:3, molar ratio), which were positively charged LPs containing DC-Chol and SM ( Table 1 ). The cellular uptake efficiencies of the LPs were comparable (Fig. 2C) , as a result, EPC containing C-type LPs exhibited the highest cellular uptake efficiency among all of the LPs examined. Based on these results, we used the lipid composition: DC-Chol/EPC/SM = 3:4:3, molar ratio for preparing the β-MEND, which has a high affinity for MIN6 cells, model pancreatic β cells.
Evaluation of the cellular uptake efficiency of β-MEND and intracellular observation of encapsulated nucleic acids in MIN6
We constructed a β-MEND encapsulating nucleic acids (Cy5 labelled oligo DNA) and evaluated the cellular uptake efficiency of this β-MEND using flow cytometry.
For the β-MEND, the envelope was comprised of the high affinity lipid composition for internalization by MIN6 cells (DC-Chol/EPC/SM = 3:4:3, molar ratio), while an R8-MEND, composed of the lipid composition (DOPE/PA/STR-R8 (9:2:1, molar ratio)) required for achieving efficient cytosolic delivery in HeLa cells, NIH3T3 cells and related cell lines [25, 26] , was prepared as the control carrier. The characteristics of the carriers are summarized in Table 2 . Their ζ-potentials were around + 25 mV and the encapsulation efficiencies were around 50%.
Flow cytometry analyses showed that β-MEND resulted in a more efficient internalization of oligo DNA into MIN6 cells than the R8-MEND and LFN Plus, a commercially available transfection reagent (Fig. 3A) . It was also confirmed that the introduction of oligo DNA by the β-MEND was proportional to the applied dose, while those by R8-MEND and LFN Plus were saturated. Moreover, intracellular observations by CLSM provided us with information regarding the intracellular fate of oligo DNA after transfection by these carriers (Fig. 3B ). In the case of the β-MEND, many green fluorescence signals derived from Cy5 labelled oligo DNA were distributed in the cytosol of MIN6 cells (Fig. 3B (a) ). On the other hand, only a few green dots were localized within the cells in the case of the R8-MEND and LFN Plus (Fig. 3B (b), (c) ). Based on these results, it was concluded that the β-MEND could achieved efficient cytosolic delivery of nucleic acids into MIN6 cells.
Analysis for the cellular uptake route of β-MEND into MIN6 cells and the evaluation of the cell viability
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To investigate the contribution of the cellular uptake pathway in the internalization of the carriers, we transfected Cy5 labelled oligo DNA into MIN6 cells using β-MEND, R8-MEND and LFN Plus in the presence or absence of specific inhibitors of each type, and then measured the internalized oligo DNA by flow cytometry (Fig. 4) .
Clathrin-mediated endocytosis is the major and best characterized endocytic pathway, and macropinocytosis and caveolae uptake represent other types of cellular uptake pathways [27, 28] . We examined the effects of the following inhibitors: a hypertonic medium to specifically inhibit clathrin-mediated endocytosis through dissociation of the clathrin lattice, amiloride to specifically inhibit macropinocytosis by inhibiting the Na/H exchange required for macropinocytosis, and filipin to specifically inhibit caveolar uptake through cholesterol depletion [27, 28] .
As shown in Figure 4A , the use of a hypertonic medium containing sucrose specifically inhibited clathrin-mediated uptake of all types of carriers by 50%. In the presence of the macropinocytosis inhibitor (amiloride), the cellular uptake of carriers was inhibited in the case of both β-MEND and R8-MEND, whereas no inhibition of the cellular uptake was observed in the case of LFN Plus (Fig. 4B) . The inhibitor of caveolar uptake (filipin) inhibited the uptake of the R8-MEND, while both the β-MEND and LFN Plus were internalized (Fig. 4C) . Taken together, these results indicate that the β-MEND involves classic clathrin-mediated endocytosis and macropinocytosis, whereas the R8-MEND utilizes all uptake pathways examined in this experiment. In the case of LFN Plus, cellular uptake would involve clathrin-mediated endocytosis as a major uptake pathway.
We also evaluated the cell viabilities of these carriers based on protein contents using MIN6 cells. As shown in Figure 5 , none of the carriers showed any cell toxicity in the case of a low applied dose. Moreover, the β-MEND and LFN Plus had no toxicity, even at a high applied dose, while the R8-MEND had a slight toxicity at an applied dose higher than 200 nM of oligo DNA concentration.
Evaluation of miR-375 knockdown by 2'-OMe RNA (anti-miR-375) delivery targeted to MIN6 using β-MEND
We attempted the knockdown of an miRNA involved in the regulation of insulin secretion (miR-375) by transfection of the anti-miR-375 into MIN6 cells using β-MEND.
It is known that miR-375 is highly expressed in pancreatic β cells, and inhibits protein expression of the phosphoinositide-dependent protein kinase 1 (Pdk1) [29] and myotrophin (Mtpn) [30] , which activate insulin secretion in response to the surrounding glucose concentration. Thus, it would be predicted that the knockdown of the miR-375
would increase the expression levels of Pdk1 and Mtpn to activate the insulin secretion. and the relative miR-375 expression level (y-axis). The results showed that more than a 90% knockdown of miR-375 occurred when the transfection of anti-miR-375 was performed at a concentration of 10 nM by the β-MEND system. It was also confirmed that the β-MEND could achieve a more efficient knockdown of miR-375 compared to LFN Plus, a commercially available transfection reagent. Moreover, western blotting analysis indicated that the expression levels of Pdk1 and Mtpn increased, when the knockdown of miR-375 was performed using the β-MEND system (Fig. S3) .
Assessment of insulin secretion in response to the surrounding glucose concentration after knockdown of miR-375 by β-MEND system
To evaluate insulin secretion in response to the surrounding glucose 25 concentration after the knockdown of miR-375, we measured the levels of insulin secretion by ELISA analysis (Fig. 7) . In this experiment, MIN6 cells were transfected with anti-miR-375 at 10, 50 and 100 nM concentrations using β-MEND or LFN Plus, and the glucose induced insulin secretion was assessed at 48 hr after the transfection. Using the β-MEND system, the insulin levels were increased when anti-miR-375 was transfected at 50 and 100 nM. While, the effect of anti-miR-375 transfection using LFN Plus on insulin levels was negligible at all concentrations examined. It was also confirmed that the insulin levels were found to be significantly increased by the β-MEND system compared to LFN Plus.
Discussion
In this study, we report on attempts to develop a nucleic acid carrier consisting of a unique lipid envelope (referred to herein as a "β-MEND") targeted to MIN6 cells.
The MIN6 cell line has been used in research on the function of β cells and diabetes therapy [7] [8] [9] , thus a nucleic acid delivery system targeted to MIN6 cells could accelerate our understanding in these fields. We focused on the development of a non-viral vector, R8-MEND [10, 11] with a high transfection activity similar to that of adenovirus [12] , efficiently packaging nucleic acids such as oligo DNA and siRNA [13] [14] [15] [16] . Unexpectedly, flow cytometry analyses and intracellular observations indicated that an efficient cellular uptake of R8-modified carriers (DOPE/PA/STR-R8 = 9:2:1, molar ratio) could not be achieved in the case of MIN6 cells, as shown in Figure 1 .
These experiments did, however, provide us with information showing that the R8-modification on the surface of LPs slightly enhanced cellular uptake in MIN6 cells, suggesting that positively charge particles would be required for the high affinity lipid composition with MIN6 cells. Moreover, we investigated cellular uptake using LPs modified with various amounts of R8 (Fig. S1 , Table S1 ). The ζ-potentials of the R8-LPs increased and were saturated at + 60 mV (Table S1) , and cellular uptake increased as a function of the amount of R8-modification on the surface of the LPs (Fig. S1 ). However, cellular uptake was not drastically increased. In the case of R8-modified carriers, the low cellular uptake in MIN6 cells might be the result of cytotoxicity, as shown in Figure 5 .
Thus, we screened a lipid composition for use in preparing the β-MEND using various cationic LPs without R8.
In the case of A-type LPs (DOTAP/EPC/Lipid X = 3:4:3, molar ratio) (Table 1) , the cellular uptake of positively charged LPs was higher than that of negatively charged LPs ( Fig. 2A) . SM, a neutral lipid, contributes to the formation of LPs with high positively charged LPs (Table 1 ) and the SM containing LP showed the highest cellular uptake. It was presumed that SM might efficiently display a positive charge on the surface of the LPs. We then screened a series of cationic lipids to identify a lipid composition for an SM containing LP using B-type LPs (Lipid X/EPC/SM = 3:4:3, molar ratio) ( Table 1) . As a result, the cellular uptake for the DC-Chol containing LP was the highest among the Btype LPs (cellular uptake, around 60 MFI; ξ-potential, around +60 mV) (Fig. 2B) , although the DOTMA containing LP had the highest positive charge (cellular uptake, around 40 MFI; ξ-potential, around +70 mV) (Table 1) . While, DDAB containing LP and R8-LP with a positive charge similar to that for DC-Chol containing LP (ξ-potential, +50-60 mV) showed the low cellular uptake in MIN6 cells (less than 20 MFI). These results suggest that a high affinity lipid composition with MIN6 cells would require an optimal positive charge and other factors. Finally, we selected an optimal main component, namely, phosphatidylcholine (PC) and phosphatidylethanolamine (PE), a neutral lipid widely used for preparation of LPs using C-type LPs (DC-Chol/Lipid X/SM = 3:4:3, molar ratio) ( Table 1 ). The cellular uptake efficiencies of the LPs were comparable (Fig.   2C ), and EPC containing C-type LPs (DC-Chol/EPC/SM = 3:4:3, molar ratio) exhibited the highest cellular uptake efficiency among all of the LPs examined (Fig. 2) .
We succeeded in constructing a β-MEND (DC-Chol/EPC/SM = 3:4:3, molar ratio) encapsulating nucleic acids, and found that its use resulted in a dramatic improvement of transfection efficiency of nucleic acids by the β-MEND system compared with the R8-MEND or LFN Plus (Figs 3) . However, the specific reason for why the lipid composition of the β-MEND is optimal for cellular uptake in MIN6 cells was unknown.
Thus, we validated route for the cellular uptake of the β-MEND in MIN6 cells to obtain a clue to this issue. As shown in Figure 4 , the β-MEND involves classic clathrin-mediated endocytosis and macropinocytosis, whereas LFN Plus involves clathrin-mediated endocytosis as a major uptake pathway. The results indicate that macropinocytosis contributes to the high cellular uptake of β-MEND in MIN6 cells, however, this hypothesis cannot be used to explain the following result. The cellular uptake of R8-MEND by MIN6 cells was significantly lower than that for the β-MEND (Fig. 3) , although the R8-MEND involves classic clathrin-mediated endocytosis, macropinocytosis and the caveolar pathway (Fig. 4) . In some pathways, the cellular uptake process involves carriers binding to the cellular surface, followed by internalization into the interior of cells. One possibility is that the high cellular uptake of the β-MEND by MIN6 cells might be mainly contributed by efficient binding to the cell rather than the internalization process. Another possibility is that β-MEND might be internalized into the interior of cells via an as-yet unknown pathway, which contributes to the high cellular uptake of the β-MEND in MIN6 cells.
As shown in Figure 6 , the β-MEND system resulted in the efficient knockdown of the targeted miR-375 when 10 nM of anti-miR-375 was transfected, while the upregulation of insulin secretion was observed for a transfection of more than 50 nM of antimiR-375 (Fig. 7) . It is likely that many factors are involved in the regulation of the insulin secretion in MIN6, thus regulation might not be achieved by only the knockdown of the miR-375, although more than a 90% knockdown occurred in the case of a transfection of 10 nM of anti-miR-375. In contrast, in the case of an anti-miR-375 transfection of more than 50 nM, other factors including functional molecules, cell signaling, external conditions might be adjusted to achieve optimal conditions for insulin secretion. 
